Study of an experimental pill for non-segmental vitiligo
Part of Skin clinical trials.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of non-segmental vitiligo (the common type that affects both sides of the body) for at least 3 months.
- Your vitiligo must cover a certain amount of skin (at least 5% of your body, including some on your face).
- Your vitiligo must not cover more than half of your body.
- You must agree not to use any other vitiligo treatments (like creams, light therapy, or procedures) during the study.
- You must not have other skin conditions that cause loss of pigment (like segmental vitiligo or piebaldism).
- You must not have any autoimmune diseases (except treated thyroid disease) and must have normal kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
This study tests a new medication called FXS5626 to help treat non-segmental vitiligo (a type of vitiligo that affects both sides of the body). It is for people who have moderate to large patches of vitiligo, especially on the face.
This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.
Hear when a new Non-segmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.